Carregant...
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX...
Guardat en:
| Publicat a: | Front Pharmacol |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Frontiers Media S.A.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6546897/ https://ncbi.nlm.nih.gov/pubmed/31191299 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2019.00524 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|